Rajiv Gandhi Cancer Institute & Research Centre Book an Appointment
alarm RGCIRC, Niti Bagh alarm Emergency - 24/7 Book an Appointment Find a Doctor
Doctor Image

Dr. Shalini Agnihotri

Onco-genomic Consultant & Sr. Research officer – Research

Specialty: Cancer Genetics

RGCIRC, Rohini, Delhi - 110085

About

Dr. Shalini Agnihotri is a Cancer Genetics Specialist and clinician-scientist with over a decade of experience in cancer research and more than six years of dedicated clinical practice in hereditary cancer genetics. After earning her Ph.D. in Prostate Cancer Biology, she transitioned from molecular cancer research to clinical cancer genetics, with a focus on translating genomic discoveries into personalized patient care.

At the Cancer Genetics Clinic, Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), New Delhi, Dr. Agnihotri provides comprehensive genetic counseling and hereditary cancer risk assessment, integrating detailed family history evaluation, risk prediction, and advanced genomic testing to guide cancer prevention, early detection, precision treatment, and long-term surveillance. Her expertise includes hereditary breast and ovarian cancer, Lynch syndrome, hereditary prostate cancer, and other inherited cancer predisposition syndromes.

Dr. Agnihotri has counseled more than 3,800 individuals and families for hereditary cancer risk and has extensive experience in cascade genetic testing, enabling at-risk relatives to benefit from timely screening, preventive interventions, and personalized risk management. Alongside her clinical practice, she is actively involved in translational cancer research with interests in cancer genomics, molecular biomarkers, polygenic risk prediction, liquid biopsy, and precision oncology. She remains committed to advancing hereditary cancer genetics in India through research, education, and compassionate patient care.

Specialized Areas

  • Hereditary breast and ovarian cancer (HBOC)
  • Prostate cancer genomics,
  • Emerging roles of microRNAs and liquid biopsy in cancer risk prediction.
    • Lynch Syndrome and Mismatch Repair Defects
    • Clinical Implementation of Multigene Panels and Variant Interpretation (ACMG/NCCN-guided)
  • Cascade Testing and Familial Risk Management in High-Risk Populations

Educational Background

Ph.D. (Biochemistry), 2018 Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow
M.Sc. (Biochemistry), 2006 — Kanpur University
B.Sc. (Hons)  2004 — Kanpur University

Experience

  • Oncogenomic Consultant, RGCIRC, Delhi: 2020- till date
  • Associate Editor in the Journal of Current Oncology
  • Research Officer, Research, 2017-till date
  • Convener of Institutional Review Board, RGCIRC, Delhi: 2017- 2019
  • Academic In-charge & DNB Coordinator of NBE, RGCIRC, Delhi: 2017-2019
  • Research Fellow, SGPGIMS, Lucknow: 2013- 2017
  • Research Fellow–SGPGIMS Lucknow: 2010 –2013
  • Research Assistant, CDRI Lucknow: 2009- 2010
  • Research Assistant, SGPGIMS Lucknow: 2008- 2009
  • Research Assistant, ITRC Lucknow: 2006- 2008

Professional Journey

ACHIEVEMENTS:

Senior Research Officer & Onco-genomic Consultant

BGCI Certified Onco-genomic Consultant

Certificate in Genetic Counselling, University of South Carolina 2020

AWARDS:

  • Agnihotri S, Mittal RD, Kapoor R, Mandhani A. Asymptomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of prostate-specific antigen. Urol Oncol. 2014Oct;32(7):946-51.10.1016/j.urolonc.2014.03.004. Epub 2014 Jul 2. PubMed PMID: 24996777. ( DUSCON AWARD ) USICON 2015
  • Micro-RNA: A potential marker to give an insight into bladder cancer biology and to characterize risk stratification for recurrence and progression. (Co-Author) Nilay Mitash, Shalini Agnihotri, Swasti Tewari, Balraj Mittal, Anil Mandhani Oral Presentation 2014 (Best Paper Award) 2014 Chandigarh

PUBLICATION

  • Agnihotri S et al. COVID-19 Vaccine Efficacy in Healthcare Workers. COVID, 2023.
    Mehta A, Agnihotri S. Founder BRCA1 mutations in Nepalese population. J Pathol Transl Med, 2022.
    Mitash N, Agnihotri S et al. miRNA-21 as recurrence marker in NMIBC. Indian J Urol.
    Agnihotri S et al. Renal cancer: Late presentation, early onset in India. Indian J Med Res, 2014.
    >12 peer-reviewed publications and >10 national conference presentations.

RESEARCH PROJECTS:

  1. Expression of androgen gene and protein to prognosticate the outcome and understand the mechanism of androgen deprivation therapy in metastatic prostate cancer.
  2. To study the impact of chronic asymptomatic prostatitis on serum PSA level by measuring seminal fluid interleukin-8 levels and its gene polymorphism.
  3. Functional analysis of pathway specific microRNAs in urinary bladder carcinoma.
  4. Identification of micro RNAs in different pathways of Metastasis in Bladder Cancer.
  5. Prediction of response to immunotherapy with expression of diagnostic and prognostic potential biomarkers in advanced renal cell carcinoma in North Indian population.
  6. To study the impact of HIF-1α, VHL and VEGF gene polymorphism on progression of RCC by quantifying their mRNA and protein product.
  7. Identification of MMP-2, MMP-9 and VEGF as a serum marker for Renal Cell Carcinoma.
  8. Correlation of Natural Killer Cell counts in whole blood and Human Leukocyte Antigen-G expression in Tumor tissue of Renal Cell Carcinoma Patients
  9. Expression of Cyclin D 1 in urine as a biomarker in Transitional cell carcinoma: A noninvasive Approach.
  10. MMR deficient Carcinoma Endometrium-How many are Lynch?
  11. Identification of clinically actionable bio-signature to incorporate in routine clinical

practice for prostate cancer management.

Papers at conferences

  1. Shalini Agnihotri, Anurag Mehta;Germline Testing for Lynch Syndrome: Need of the hour ASHG 2023
  2. Shalini Agnihotri, Anil Mandhani, Anurag Mehta,Sudhir Rawal; Increased expression of Cyclin D as a biomarker in Transitional cell carcinoma: A noninvasive Approach EUA 2020
  3. Is there any association between raised interleukin 8 level in the prostatic fluid in men with chronic asymptomatic prostatitis with elevated PSA and genetic polymorphism? Shalini Agnihotri,# R.D.Mittal, Rakesh Kapoor, Anil Mandhani USICON 2013 held in Pune.
  4. Two weeks of antibiotics and anti-inflammatory would reduce un-necessary biopsy in men with PSA range between 4-20ng/ml Shalini Agnihotri, Shamim Ahmad, Rakesh Kapoor, Anil Mandhani USICON 2013 held in Pune. Oral Presentation
  5. Clinical predictors for Castrate resistant prostate cancer in locally advanced and metastatic prostate cancer.(Co-author) Nilay Mitash, Shalini Agnihotri, Shamim Ahmad, Rakesh Kapoor, Ruchir Maheswari, Anil Mandhani USICON 2013 held in Pune.
  6. Role of matrix metalloproteinases-2 and matrix metalloproteinases-9 in renal cell carcinoma.(Co-Author) Shamim Ahmad, Shalini Agnihotri, Nilay Mitash, Anil Mandhani USICON 2013 held in Pune.
  7. Micro-RNA: A potential marker to give an insight into bladder cancer biology and to characterize risk stratification for recurrence and progression. (Co-Author) Nilay Mitash, Shalini Agnihotri, Swasti Tewari, Balraj Mittal, Anil Mandhani Oral Presentation Chandigarh 2014
  8. The outcome of PSA screening in Symptomatic Men in North India. Shalini Agnihotri; Mamta Singh;Rama D. Mittal. Rakesh Kapoor; Anil Mandhani USICON-2011 21st-23rd January 2011 at SGPGIMS, Lucknow India. Oral Presentation
  9. Association of TNF alpha polymorphism with altered sperm concentration and motility in infertile men of Indian population.(Co author) Shukla KK,Shalini Agnihotri,Abhishek Gupta,Mahdi AA, Mishra V, Sankhwar SN. 11 April 2012, Poster Presentation

Membership

  • ASHG membership